| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6178231 | European Urology | 2011 | 15 Pages |
Abstract
The treating oncologist should try to manage side-effects associated with targeted therapy using supportive and pharmacologic interventions. Severe toxicity requires external specialist consultation and treatment suspension and/or dose reduction. Experimental data about the management of targeted therapy-related toxicity in mRCC is lacking and required in this setting.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Giuseppe Di Lorenzo, Camillo Porta, Joaquim Bellmunt, Cora Sternberg, Ziya Kirkali, Michael Staehler, Steven Joniau, Francesco Montorsi, Carlo Buonerba,